Study Reveals Serious Genomic Risks of CRISPR-Cas with AZD7648 Molecule

Despite the setback, researchers remain optimistic about refining CRISPR-Cas technologies. ETH Zürich plans to explore safer alternatives, including combinations of molecules to encourage HDR without causing genome instability. While AZD7648's side effects highlight challenges, the broader success of CRISPR-based therapies, such as curing sickle cell anemia in clinical settings, underscores the transformative potential of gene editing when safety and precision are ensured.

Or more in details, visit the full article here.